StockNews.AI
JAGX
StockNews.AI
126 days

Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting

1. Jaguar's Mytesi® shows significant results for breast cancer patient subgroup. FDA meeting planned for crofelemer approval in 2025.

3m saved
Insight
Article

FAQ

Why Bullish?

Positive results from the OnTarget study may enhance investor confidence, following historical trends from drug approvals.

How important is it?

The article highlights important study results and upcoming FDA discussions, indicating a strategic path forward.

Why Long Term?

If FDA approval succeeds, it could significantly boost revenues and market perception over time.

Related Companies

MYTENPO
The statistically significant responder analysis results for Mytesi® (crofelemer) in the Phase 3 OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poster presentation at the San Antonio Breast Cancer Symposium Late-breaker abstract accepted by MASCC shows additional significant results for breast cancer subgroup Jaguar planning to meet with FDA in Q2 2025 to discuss possible pathways for crofelemer approval for prophylaxis of diarrhea in patients with breast cancer A second late-breaker abstract, related to the results of a screening survey of cancer patients about oral mucositis and a follow-up focus group, has also been accepted for presentation at MASCC's 2025 Annual Meeting SAN FRANCISCO, CA / ACCESS Newswire / April 15, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") family company Napo Pharmaceuticals ("Napo") today announced that the late-breaker abstract Napo submitted to MASCC on additional significant results in adult breast cancer patients from the OnTarget study has been accepted for presentation as an oral rapid e-poster at MASCC's June 26-28, 2025 Annual Meeting in Seattle, Washington. The authors include Pravin Chaturvedi, PhD, who is Jaguar's Chief Scientific Officer and Chair of Napo's Scientific Advisory Board, as well as leading oncologists and cancer patient advocates.

Related News